FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945590213> ?p ?o ?g. }

• W2945590213 endingPage "580" @default.
• W2945590213 startingPage "563" @default.
• W2945590213 abstract "Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs. Immune-checkpoint inhibitors (ICIs) have dramatically improved the survival of patients with certain forms of cancer; however, these agents also have adverse effects that are often quite different to those of more traditional cancer therapies. In this Review, the authors describe the epidemiology, treatment and management of the various immune-related adverse events that can occur in patients receiving ICIs." @default.
• W2945590213 created "2019-05-29" @default.
• W2945590213 creator A5000749379 @default.
• W2945590213 creator A5013756173 @default.
• W2945590213 creator A5019240890 @default.
• W2945590213 creator A5020398369 @default.
• W2945590213 creator A5020492229 @default.
• W2945590213 creator A5026782033 @default.
• W2945590213 creator A5028479135 @default.
• W2945590213 creator A5032536875 @default.
• W2945590213 creator A5041800046 @default.
• W2945590213 creator A5046064634 @default.
• W2945590213 creator A5050524301 @default.
• W2945590213 creator A5061159661 @default.
• W2945590213 creator A5062578054 @default.
• W2945590213 creator A5063300526 @default.
• W2945590213 creator A5074293408 @default.
• W2945590213 creator A5088720257 @default.
• W2945590213 creator A5090256570 @default.
• W2945590213 date "2019-05-15" @default.
• W2945590213 modified "2023-10-18" @default.
• W2945590213 title "Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance" @default.
• W2945590213 cites W1185432402 @default.
• W2945590213 cites W1556990476 @default.
• W2945590213 cites W1570988221 @default.
• W2945590213 cites W1605315445 @default.
• W2945590213 cites W1664299218 @default.
• W2945590213 cites W1914776013 @default.
• W2945590213 cites W1916602633 @default.
• W2945590213 cites W1984592499 @default.
• W2945590213 cites W1995090169 @default.
• W2945590213 cites W2002673340 @default.
• W2945590213 cites W2013013791 @default.
• W2945590213 cites W2022073464 @default.
• W2945590213 cites W2029073555 @default.
• W2945590213 cites W2036195858 @default.
• W2945590213 cites W2051357882 @default.
• W2945590213 cites W2052078062 @default.
• W2945590213 cites W2054666183 @default.
• W2945590213 cites W2085247907 @default.
• W2945590213 cites W2091366828 @default.
• W2945590213 cites W2091536187 @default.
• W2945590213 cites W2097995306 @default.
• W2945590213 cites W2100127605 @default.
• W2945590213 cites W2104347254 @default.
• W2945590213 cites W2104504726 @default.
• W2945590213 cites W2106426147 @default.
• W2945590213 cites W2107150019 @default.
• W2945590213 cites W2109653150 @default.
• W2945590213 cites W2114256900 @default.
• W2945590213 cites W2118471749 @default.
• W2945590213 cites W2128035403 @default.
• W2945590213 cites W2128758225 @default.
• W2945590213 cites W2130085832 @default.
• W2945590213 cites W2130822830 @default.
• W2945590213 cites W2131640081 @default.
• W2945590213 cites W2132916434 @default.
• W2945590213 cites W2133075384 @default.
• W2945590213 cites W2136746908 @default.
• W2945590213 cites W2136795316 @default.
• W2945590213 cites W2139191751 @default.
• W2945590213 cites W2141427930 @default.
• W2945590213 cites W2142449922 @default.
• W2945590213 cites W2142754164 @default.
• W2945590213 cites W2152897456 @default.
• W2945590213 cites W2154441168 @default.
• W2945590213 cites W2155464214 @default.
• W2945590213 cites W2156353875 @default.
• W2945590213 cites W2165456770 @default.
• W2945590213 cites W2166662937 @default.
• W2945590213 cites W2171853585 @default.
• W2945590213 cites W2193769500 @default.
• W2945590213 cites W2198093519 @default.
• W2945590213 cites W2239087114 @default.
• W2945590213 cites W2275606382 @default.
• W2945590213 cites W2291096806 @default.
• W2945590213 cites W2301851804 @default.
• W2945590213 cites W2323655202 @default.
• W2945590213 cites W2329871425 @default.
• W2945590213 cites W2335651231 @default.
• W2945590213 cites W2338242614 @default.
• W2945590213 cites W2341408002 @default.
• W2945590213 cites W2344489622 @default.
• W2945590213 cites W2411407183 @default.
• W2945590213 cites W2413514895 @default.
• W2945590213 cites W2417721321 @default.
• W2945590213 cites W2418354692 @default.
• W2945590213 cites W2428236439 @default.
• W2945590213 cites W2428806539 @default.
• W2945590213 cites W2478478625 @default.
• W2945590213 cites W2501357434 @default.
• W2945590213 cites W2508205285 @default.
• W2945590213 cites W2510686645 @default.
• W2945590213 cites W2512251660 @default.
• W2945590213 cites W2512614851 @default.
• W2945590213 cites W2522337762 @default.
• W2945590213 cites W2525217971 @default.
• W2945590213 cites W2527905628 @default.

• next